Compounds targeting the PI3K/Akt/mTOR pathway had an effect on the viability of CP CML MNCs ex vivo, but the leukemia-specificity was modest. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.